Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Revisit Every OncLive On Air Episode From July 2025

July 31st 2025

Read a recap of the episodes of OncLive On Air that debuted in July 2025.

Understanding PSA Threshold in Metastatic Castration-Sensitive Prostate Cancer

July 30th 2025

Panelists discuss how data from the International Registry for Men with Advanced Prostate Cancer (IRONMAN) demonstrates that achieving a prostate-specific antigen (PSA) threshold below 0.2 ng/mL at 6 to 12 months is associated with improved progression-free survival and overall survival regardless of treatment regimen.

PSA Nadir and Response Assessment in Metastatic Castration-Sensitive Prostate Cancer

July 30th 2025

Panelists discuss how prostate-specific antigen (PSA) nadir serves as a crucial prognostic marker in metastatic castration-sensitive prostate cancer (mCSPC), with faster drops to lower levels (particularly below 0.2) correlating with better outcomes, whereas imaging frequency should be customized based on clinical status and PSA kinetics.

Lineage Plasticity and Treatment Resistance Highlight Need for Personalized mCRPC Strategies

July 28th 2025

Jue Wang, MD, outlines how prolonged androgen suppression may drive prostate cancer evolution.

Real-World Treatment Gaps in mCRPC Reinforce the Need for Personalized Selection and Sequencing

July 23rd 2025

Jue Wang, MD, discusses persistent gaps between clinical advances and real-world care and the evolving role of personalized treatment strategies in mCRPC.

Key Takeaways in mCSPC: Combination Therapy and Germline Testing Is the New Standard of Care

July 23rd 2025

Panelists discuss how androgen deprivation therapy (ADT) monotherapy is no longer acceptable for metastatic castration-sensitive prostate cancer (mCSPC), emphasizing that combination therapy with androgen receptor (AR) pathway inhibitors or chemotherapy plus universal germline testing should be the new standard of care.

Expert Perspectives: ARANOTE: Subgroup Analysis in Black Patients

July 23rd 2025

Panelists discuss how the ARANOTE trial’s subgroup analysis of 65 Black patients (primarily from Brazil and South Africa) demonstrated consistent treatment benefits and highlights the importance of diversity in clinical trials to address health care disparities and potential biological differences across populations.

Talazoparib Plus Tazemetostat Is Safe, Generates Signs of Clinical Benefit in mCRPC

July 22nd 2025

The combination of talazoparib and tazemetostat was safe and led to PSA reductions in certain patients with metastatic castration-resistant prostate cancer.

Dr McKay on the Safety of Olaparib and Radium-223 in mCRPC With Bone Metastases

July 22nd 2025

Rana R. McKay, MD, FASCO, discusses the safety profiles of olaparib plus radium-223 vs radium-223 monotherapy in mCRPC.

Darolutamide Plus ADT Gains EU Approval for mHSPC

July 21st 2025

Darolutamide receives EU approval with ADT for metastatic hormone-sensitive prostate cancer.

HARMONY Study Aims to Personalize PARP Inhibition in mHSPC Through Adaptive Design, Diverse Patient Enrollment

July 21st 2025

Qian (Janie) Qin, MD, discusses the importance of early molecular testing, evolving PARP inhibitor strategies, and the phase 2 HARMONY trial in mHSPC.

Interpreting ARANOTE: Darolutamide in Doublet and Triplet Therapy for Metastatic Castration-Sensitive Prostate Cancer

July 16th 2025

Panelists discuss how the ARANOTE trial’s progression-free survival benefits with darolutamide inform treatment selection between doublet and triplet approaches, emphasizing personalized decision-making based on tumor burden, patient performance status, and the “first shot, best shot” treatment philosophy.

Long-Term Efficacy of Doublets—the ARCHES 5-Year Update

July 16th 2025

Panelists discuss how the ARANOTE trial’s quality-of-life data and the ARCHES trial’s 5-year follow-up demonstrate sustained benefits of doublet therapy, with enzalutamide plus ADT showing a 3-year overall survival improvement in high-volume patients.

Lutetium Lu 177 Vipivotide Tetraxetan Positioned for Earlier Use in mCRPC, While Radium-223 Sequencing Requires Further Clarification

July 15th 2025

Qian (Janie) Qin, MD, discusses the current arsenal of radioligand therapies in metastatic castration-resistant prostate cancer.

Dr Qin on Ongoing Investigations of Radium-223 in mCRPC

July 15th 2025

Qian (Janie) Qin, MD, discusses efforts to elucidate the optimal use of radium 223 plus enzalutamide in metastatic castration-resistant prostate cancer.

Early Safety Data Show Tolerability of Apalutamide Plus Carotuximab in Metastatic CRPC

July 15th 2025

Apalutamide plus carotuximab has been demonstrated to be well tolerated in patients with metastatic castration-resistant prostate cancer

Pasritamig Displays Safety, Durable Disease Control in Heavily Pretreated mCRPC

July 14th 2025

Pasritamig was safe and produced durable responses in heavily pretreated metastatic castration-resistant prostate cancer.

The OncFive: Top Oncology Articles for the Week of 7/6

July 12th 2025

The FDA approves Y-90 resin microspheres in HCC, the sNDA for decitabine/cedazuridine plus venetoclax in AML is under review, and more.

Dr Saad on the Efficacy and Safety of Radium-223 Plus Enzalutamide in mCRPC

July 11th 2025

Fred Saad, CQ, MD, FRCS, FCAHS, discusses efficacy and safety data from the PEACE study of radium-223 and enzalutamide in mCRPC.

Enzalutamide Plus Leuprolide Yields OS Benefit in nmHSPC With Biochemical Recurrence

July 10th 2025

The combination of enzalutamide and leuprolide improved OS vs leuprolide alone in nmHSPC with high-risk biochemical recurrence at high risk for metastasis.